Veeva Systems Inc. Share Price Target ‘$241.47’, now 14.8% Upside Potential

DirectorsTalk Interviews

Veeva Systems Inc. which can be found using ticker (VEEV) now have 24 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between $270.00 and $200.00 calculating the average target share price we see $241.47. (at the time of writing). Now with the previous closing price of $210.27 this would imply there is now a potential upside of 14.8%. The day 50 moving average is $213.11 and the 200 day moving average is $202.61. The market capitalization for the company is 33.93B. The current share price for the company is: $209.96 USD

The potential market cap would be $38,967,399,440 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 65.41, revenue per share of $14.72 and a 5.01% return on assets.

Veeva Systems Inc. is a provider of industry cloud solutions for the global life sciences industry. The Company’s offerings span cloud software, data, and business consulting and are designed to meet the needs of its customers and their most strategic business functions from research and development (R&D) to commercialization. The Company’s industry cloud solutions for the life sciences industry are grouped into two major product families: Veeva Development Cloud and Veeva Commercial Cloud. Veeva Development Cloud includes application suites for the clinical, regulatory, and safety functions of life sciences companies, all built on its proprietary Veeva Vault platform. Veeva Commercial Cloud includes solutions for the sales, medical affairs, and marketing functions of a life sciences company. Its software offerings include Veeva CRM, Veeva Vault PromoMats, Veeva Vault Medical, and Veeva Crossix. Its data offerings include Veeva OpenData, Veeva Link, and Veeva Compass.

Share on:

Latest Company News

Genflow Biosciences reports early findings from SIRT6 gene therapy study

Genflow Biosciences reports early findings from its SIRT6 gene therapy study in older dogs, with further monitoring planned over...

Ilika CEO to discuss battery gigafactory development at Barcelona industry forum

Ilika CEO Graeme Purdy is set to speak at the December 2026 Barcelona battery gigafactory forum, bringing the company's...

Investors demand clear returns as AI spending comes under scrutiny

Investors are demanding clearer returns from AI spending as technology shares face pressure, with corporate earnings, data centre investment...

Novo Nordisk deal puts focus on next generation of oral GLP-1 treatments

Novo Nordisk secures rights to Hengrui's investigational HRS-1596 in a potential $2.6bn deal, targeting the development of once-weekly oral...

itim Group targets retail AI market with new platform launch

ITIM Group is targeting the retail AI market with itimAIQ, a new platform designed to automate operations, improve efficiency...

Drax sets date for 2026 Capital Markets Day and trading update

Drax Group will host its Capital Markets Day on 23 November 2026, providing investors and analysts with a management...

    Search